Repare Therapeutics Inc. (NASDAQ: RPTX) disclosed significant strategic adjustments in a recent SEC 8-K filing. The precision oncology company declared preliminary unaudited financial data, indicating ...
As top pharma executives arrive in San Francisco, CA, to attend the J.P. Morgan Healthcare Conference next week, biotech ...
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback